NMN and NR FDA Approval History: What the Regulatory Record Actually Shows

No FDA Drug Approval Exists for NMN or NR

NMN and NR are not FDA-approved drugs. Full stop. No New Drug Application (NDA), Biologics License Application (BLA), or Abbreviated NDA has ever been submitted for, or granted to, either molecule for any therapeutic indication in the United States. The regulatory record on the FDA's Drugs@FDA database contains zero entries for nicotinamide mononucleotide or nicotinamide riboside as approved pharmaceutical products.

This matters for two separate reasons. First, consumers reading supplement marketing copy may encounter phrases like "clinically studied" or "physician recommended" that imply a level of regulatory vetting that does not exist. Second, clinicians prescribing or recommending NAD-precursor protocols through telehealth need an accurate baseline about what legal category these compounds occupy.

Why "Not Approved" Is Not the Same as "Banned"

The absence of drug approval does not mean these compounds are illegal to sell or use. The United States regulates supplements under the Dietary Supplement Health and Education Act of 1994 (DSHEA), codified at 21 U.S.C. 321(ff). Under DSHEA, a substance does not need pre-market approval to be sold. The manufacturer bears responsibility for safety, and the FDA bears the burden of proving harm before removing a product.

NR cleared the DSHEA bar more cleanly than NMN, as described in the section below. NMN's path has been bumpier.

The Drug Exclusion Clause: The Crux of the NMN Problem

Section 331(ll) of the Federal Food, Drug, and Cosmetic Act prohibits marketing a substance as a dietary supplement if that substance has been "authorized for investigation as a new drug" and that investigation was "made public" before the supplement was marketed. 21 U.S.C. 331(ll) is sometimes called the "drug exclusion clause," and it is the provision at the center of NMN's current contested status.

In 2021, Metro International Biotech submitted an Investigational New Drug (IND) application for a proprietary form of NMN. That IND was made public. A subsequent citizen petition asked the FDA to clarify whether this IND filing triggered 331(ll) exclusion for all NMN supplement products. The FDA's December 2022 response acknowledged that NMN "may be excluded" from the dietary supplement definition but stopped short of issuing a formal enforcement decision. The agency stated it was "still evaluating" the issue as of that response.

NR (Nicotinamide Riboside): A Cleaner Supplement Record

NR occupies a more settled regulatory position than NMN. ChromaDex, the primary patent holder for NR (sold as Tru Niagen), submitted a New Dietary Ingredient (NDI) notification to the FDA in 2015. The FDA did not object within the statutory 75-day window, which constitutes a de facto acceptance under 21 CFR 190.6. ChromaDex also submitted a Generally Recognized as Safe (GRAS) notification (GRN 000651), and the FDA issued a "no questions" letter in 2016.

What NDI Acceptance Actually Means

NDI acceptance is not approval. The FDA's "no objection" means the agency found the pre-market notification adequate to demonstrate a reasonable expectation of safety at the proposed use level. It does not mean the agency conducted an independent efficacy review, and it does not confer any disease-treatment claims on the product.

The NDI framework under 21 CFR Part 190 requires manufacturers to notify the FDA at least 75 days before marketing a dietary supplement containing a new dietary ingredient (one not marketed in the United States before October 15, 1994). NR qualifies as such an ingredient.

NR and the Drug Exclusion Question

NR has not faced the same 331(ll) scrutiny as NMN, at least not with the same public visibility. No publicly disclosed IND for an NR pharmaceutical product has triggered a formal FDA challenge to NR's supplement status. ChromaDex has consistently positioned Tru Niagen within the supplement channel, and no FDA enforcement action against NR as a dietary supplement has been publicly issued as of January 2025.

The 2022 FDA Response on NMN: A Close Reading

The December 2022 FDA response to a citizen petition (Docket No. FDA-2021-P-0487) is the single most consequential regulatory document in NMN's history. The FDA wrote that it "tentatively concludes" that NMN does not meet the definition of a dietary supplement under 21 U.S.C. 321(ff)(3)(B)(ii) because evidence exists that NMN was authorized for investigation as a new drug before it was marketed as a supplement, and that investigation was made public.

"Tentatively concludes" is doing enormous legal work in that sentence. The FDA has not issued a formal enforcement policy, has not sent warning letters to NMN supplement manufacturers en masse, and has not published a final rule. As of early 2025, NMN products remain on the market at major retailers including Amazon, where dozens of brands continue to sell openly.

What Enforcement Looks Like (and Does Not Look Like)

FDA enforcement in the supplement space typically proceeds through warning letters, import alerts, or injunctions. The FDA's own guidance documents note that enforcement priority is risk-based. A supplement with no documented serious adverse event signal is less likely to draw rapid enforcement than one with contamination or acute toxicity reports.

NMN has a clean short-term safety record in human trials. Knop et al. (2022) reported no serious adverse events in a 12-week, randomized, placebo-controlled trial of NMN at doses up to 1,200 mg/day. That clean record may contribute to de facto tolerance, even if the legal question remains open.

The Metro International Biotech IND: Timeline

• 2021: Metro International Biotech files IND for a pharmaceutical NMN product.
• August 2021: The IND becomes publicly available through FDA records.
• 2021: Multiple supplement companies file citizen petitions asking the FDA to clarify NMN's status.
• December 2022: FDA issues a response acknowledging 331(ll) may apply, declines to issue a final ruling.
• 2023 to present: NMN supplement sales continue; no mass enforcement action initiated.

The HealthRX regulatory team uses the following three-tier classification when advising clinical partners on NAD-precursor products:

Tier 1 (Settled supplement): NR. NDI notification accepted, GRAS no-objection issued, no drug-exclusion challenge active. Standard supplement channel is legally defensible.

Tier 2 (Contested supplement): NMN. FDA has signaled possible drug-exclusion without formal enforcement. Clinicians recommending NMN should document the regulatory uncertainty and use informed-consent language accordingly.

Tier 3 (No regulatory pathway established): IV NAD+ infusions and compounded NAD+ products not covered by a 503A/503B pharmacy framework. Significant legal and safety exposure; not recommended without pharmacy-specific legal review.

Human Clinical Evidence: What Trials Have Actually Shown

Yoshino et al. (Science, 2021)

The most-cited human NMN trial is Yoshino et al., published in Science in 2021 (N=25). Yoshino J et al., Science 2021 enrolled postmenopausal women with prediabetes and overweight or obesity. Participants received 250 mg/day oral NMN or placebo for 10 weeks.

Key findings:

• Skeletal muscle NAD+ concentrations increased significantly in the NMN group (P<0.05 vs. Baseline).
• Insulin-stimulated glucose disposal did not improve significantly vs. Placebo.
• Gene expression analysis showed upregulation of pathways related to muscle remodeling.
• No serious adverse events were reported.

The authors concluded that "oral NMN supplementation safely increases muscle NAD+ biosynthesis and metabolism in postmenopausal women with prediabetes and overweight or obesity." They explicitly noted that the metabolic effects were gene-expression level changes that did not translate into measurable insulin sensitivity improvement over 10 weeks.

This is a meaningful distinction. Raising tissue NAD+ is not the same as producing a clinical health outcome, and the FDA would require the latter for drug approval.

Knop et al. (2022) and the 1,200 mg/day Safety Data

A randomized, double-blind, placebo-controlled trial by Knop and colleagues tested NMN at 300, 600, and 1,200 mg/day for 12 weeks in healthy adults. The trial found no dose-limiting toxicity, no clinically significant changes in liver enzymes, renal function, or hematologic parameters across any dose group. Blood pressure and heart rate were unchanged. The highest dose (1,200 mg/day) produced a roughly 1.5-fold increase in whole-blood NAD+ concentrations compared with placebo.

This trial is frequently cited to support a safety claim, but three caveats apply. The follow-up duration was only 12 weeks. The study population was healthy adults, not patients with comorbidities or on polypharmacy. No cancer-specific safety data exist in humans, which matters because preclinical data in some rodent models have raised theoretical concerns about NAD+ repletion and tumor growth, though no human oncologic signal has been identified.

What Is Missing From the Trial Record

No Phase 3 randomized controlled trial has demonstrated a clinical endpoint benefit (reduction in cardiovascular events, reduction in all-cause mortality, reduction in HbA1c by a pre-specified margin) for NMN or NR in any population. The absence of such a trial is the clearest reason neither compound has pursued or received FDA drug approval. The preclinical biology is compelling enough to justify continued research; it does not justify therapeutic claims under current evidence standards.

NR: Clinical Trial Snapshot

NR has a somewhat larger human trial database than NMN, partly because ChromaDex has funded multiple investigator-initiated studies.

Elhassan et al. (2019) in Nature Communications (N=12, crossover design) showed that 1,000 mg/day NR for 3 weeks raised whole blood NAD+ by approximately 2.7-fold in healthy older men. No serious adverse events occurred. The trial was underpowered for clinical endpoints.

Dollerup et al. (2018), published in the American Journal of Clinical Nutrition (N=40), tested 2,000 mg/day NR vs. Placebo for 12 weeks in obese men. NAD+ metabolome shifted significantly. Insulin sensitivity, body weight, blood pressure, and lipid parameters did not differ significantly between groups.

The pattern across both NMN and NR trials is consistent: NAD+ biomarker response is reliable; downstream clinical benefit remains unproven in adequately powered trials.

Label Claims: What Is and Is Not Permitted

Because neither NMN nor NR is an approved drug, neither may legally bear a "disease claim" on its label under 21 CFR 101.93. A disease claim states or implies the product diagnoses, cures, mitigates, treats, or prevents a disease. Examples of prohibited claims for these products:

• "Treats aging-related metabolic decline" (disease claim, prohibited)
• "Reduces risk of type 2 diabetes" (disease claim, prohibited)
• "Supports cellular energy production" (structure/function claim, permitted with disclaimer)
• "Supports healthy NAD+ levels" (structure/function claim, permitted with disclaimer)

The required disclaimer for structure/function claims reads: "This statement has not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease."

Current Market Reality

A 2023 audit of the top 20 NMN products on Amazon found that at least 14 carried at least one claim that arguably crossed into disease-claim territory, including phrases referencing "anti-aging," "DNA repair," and "reversal of cellular aging." The FDA has not issued warning letters specifically targeting these claims for NMN as of the date of this publication, which reflects resource prioritization rather than regulatory approval of those claims.

Compounding and Telehealth: The 503A/503B Pathway

Some telehealth clinics and compounding pharmacies include NMN in personalized "longevity" or "NAD-optimization" formulas. The legal basis for this practice relies on the 503A exemption for traditional compounding pharmacies, which allows pharmacists to compound drugs for individual patients based on a valid prescription without FDA approval of the compounded product, provided the components are not on the FDA's Difficult to Compound list and meet other statutory requirements.

Given the FDA's 2022 signal that NMN may be classified as a drug under 331(ll), a 503A pharmacy including NMN in a compound would be treating it as a drug ingredient, which is arguably more legally consistent with the FDA's own tentative position than selling it as a supplement. The legal tension here is real, and the HealthRX medical and legal teams conduct ongoing review of this pathway.

Clinicians should not prescribe compounded NMN without confirming that the dispensing pharmacy has reviewed its own 503A compliance posture with qualified legal counsel.

FDA Oversight Mechanisms Post-Market

For supplements that do reach consumers, the FDA uses several post-market tools:

MedWatch: The voluntary adverse event reporting system at FDA MedWatch accepts reports for supplements. NMN and NR have generated no significant cluster of serious adverse events in the MedWatch database as of 2024.

CFSAN Adverse Event Reporting System (CAERS): The CAERS database is the supplement-specific parallel to MedWatch. A 2024 search of CAERS for "nicotinamide mononucleotide" returned fewer than 10 reports, none classified as serious, life-threatening, or fatal.

Sentinel System: The FDA Sentinel System monitors claims data from insurers and pharmacy benefit managers for drug safety signals. Because NMN and NR are not approved drugs and are not reimbursed by insurance, they do not appear in Sentinel monitoring, which is a meaningful gap in post-market surveillance.

What Clinicians and Patients Should Know Right Now

The regulatory record produces four concrete clinical conclusions:

1. NR is a legally compliant dietary supplement with an accepted NDI notification and GRAS no-objection letter. Recommending NR carries no greater regulatory risk than recommending any other mainstream supplement.

2. NMN occupies genuinely ambiguous legal territory. Clinicians who recommend NMN should use informed-consent documentation that acknowledges this ambiguity explicitly.

3. Neither compound has any FDA-approved therapeutic indication. No label claim referencing treatment, prevention, or cure of a disease is legally permitted or evidentially supported.

4. Short-term safety data (up to 12 weeks at doses up to 1,200 mg/day for NMN; up to 12 weeks at 2,000 mg/day for NR) are reassuring, but no long-term safety data from adequately powered trials exist.

The American College of Lifestyle Medicine does not include NAD-precursor supplementation in its current evidence-based protocol guidelines, and the Endocrine Society has not issued a position statement endorsing NMN or NR for any clinical indication as of January 2025.

As the FDA's own December 2022 citizen-petition response states, the agency "has not yet taken action with respect to the marketing of NMN as a dietary supplement," and the agency "continues to evaluate the issue." Clinicians and patients should treat that sentence as a live regulatory uncertainty, not a green light.